The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

A specialty pharmacy company agreed to a $1.67 million settlement that it gave inventory management systems to retina ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema ...

Pravin U. Dugel, MD, Ocular’s Executive Chairman, President and CEO, will provide an update regarding the enrollment status of SOL-R, the Company’s second registrational trial of AXPAXLI™ for the ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the ...

and recommend treatments such as lifestyle adjustments, vitamins, or medical interventions like injections to help preserve vision. At Evergreen Retina, we specialize in diagnosing and treating ...

The following is a summary of “How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient ...

ArMaDa clinical trial is set to assess the safety and efficacy of unilateral subretinal administration of OCU410 in patients ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced central ...

Investigators conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of brolucizumab ...